no more compounding glp 1 drugs GLP-1 weight loss are back in the news GLP-1 Compounding: When Innovation May

From the phase 3 trials at the 9 mg and 12 mg doses: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% with placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% with placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% with placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) Compare those numbers to Mounjaro and the difference is clear

Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage

PCSK2) is highly expressed in the pancreas [151], and its expression in -cells results in cleavage of Gcg into pancreatic type glucagon, GRPP, MPGF, and a small intervening peptide (IP1)

doi: 10.1177/1479164111404257 [DOI] [PubMed] [Google Scholar] 7

Shes achieved 8% weight loss and HbA1c reduction from 8.1% to 7.2% over 4 months

However, these agents slow gastrointestinal motility, which can lead to side effects of increased gastro-oesophageal reflux, nausea, vomiting, constipation or paradoxical diarrhoea